Want to see PRQR full AI Analyst Report?
PRQR Stock Chart & Stats
$1.99
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.99
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.33 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$161.20M
Enterprise Value$85.27M
Total Cash (Recent Filing)$81.17M
Total Debt (Recent Filing)$13.70M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Jul 30, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue6.32
Enterprise Value/Gross Profit6.67
Enterprise Value/Ebitda-2.08
Forecast
1Y Price Target
$8.67Price Target Upside335.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$20.65M
Bulls Say, Bears Say
Bulls Say
Platform Validation (Axiomer)Clinical target engagement for AX-0810 provides the first human validation of ProQR's Axiomer RNA editing platform. Dose-dependent biomarker shifts and a favorable safety profile support platform credibility, enabling broader clinical programs and partner interest over the next 2–6+ months as development advances.
AI-enabled Discovery PartnershipThe Ginkgo partnership and AI advisory board materially strengthen ProQR's discovery engine by enabling high-throughput data generation and ML model training. This should sustainably improve candidate selection and speed to clinic, expanding pipeline breadth and lowering long-term discovery risk for RNA-editing programs.
Strengthened Governance And Clinical ExpertiseAdding a seasoned drug-development executive to the board enhances clinical and regulatory oversight at a strategic level. This durable governance improvement supports more rigorous trial design, regulatory interactions and partner confidence, reducing execution risk as programs move into pivotal studies.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates the company cannot internally fund development. Over 2–6 months this requires continued external financing, which can constrain strategic options, delay programs if funding gaps emerge, and heighten dilution or partnership dependency risk.
Declining Revenue And Large Operating LossesA falling revenue trend coupled with very large negative operating margins shows the cost base vastly exceeds current income. This structural profitability gap limits reinvestment capacity and underscores that commercial or milestone revenues must materialize to shift long-term economics.
Reliance On Equity Raises / Dilution RiskFrequent equity financings and shareholder-authorized capital increases highlight dependence on dilutive funding to sustain operations. Over the medium term this can dilute existing holders, signal limited alternative cash sources, and create pressure to secure partnerships or clinical milestones to reduce funding needs.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.33 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $161.20M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Jul 30, 2026 which is in 31 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on May 12, 2026. The company reported -$0.148 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.011.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.13.
How many shares outstanding does ProQR have?
ProQR has 105,361,060 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.148 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -0.621%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (335.51% Upside)
$8.67 (335.51% Upside)
Hedge Fund Trend
Increased
By 91.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-86.47%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.67
▲(335.51% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.85% Mutual Funds
23.37% Other Institutional Investors
74.32% Public Companies and
Individual Investors